Novozymes (CPSE:NZYM B) has acquired a majority stake in Synergia Life Sciences

Synergia Life Sciences

Headquartered in Mumbai, India, Synergia is a leading producer of spore probiotics and vitamin K2-7 for the global healthcare industry. Synergia operates three production sites in India and possesses a portfolio of clinically documented spore strains for dietary food supplement and functional food applications. The company’s flagship vitamin K2-7 brand, MenaquinGold, is offered alongside a differentiated product portfolio of microbiome therapeutics, probiotics and enzymes.

The Deal

By acquiring Synergia, Novozymes strengthens and accelerates its position in human health and functional foods, adding strong developing and manufacturing capabilities in spore probiotics. The Synergia product portfolio further enables and supports growth in Novozymes’ BioHealth platform. The acquisition offers a scientifically proven portfolio that strengthens Novozymes’ human health business and accelerates its functional food offerings while vertically integrating its supply chain with a key supplier. View the press release here.

Our Perspective

Gaurav Marathe, Managing Director and Chief Executive Officer of Lincoln India, stated, “Human health and functional foods is a growing area of expertise for Lincoln. We were pleased to be able to partner with Novozymes in support of this transaction, which had a high level of complexity and required speed in execution and seamless coordination to achieve the desired outcome. Novozymes’ long-term strategy for its BioHealth platform will find a very complementary asset in Synergia, which will help further the business globally.” Tony Crisman, Managing Director in Lincoln’s Healthcare Group, added, “This transaction showcases Lincoln’s integrated global capabilities to support market leaders, such as Novozymes OneHealth with their critical, cross-border, strategic acquisition initiatives.”

Novozymes

Headquartered in Bagsværd, Denmark, Novozymes is a global leader in biological solutions and the world’s largest provider of enzyme and microbial technologies. Novozymes’ BioHealth platform leverages the company’s strong scientific capabilities and ability to combine microbes, pre- and probiotics, with enzymes and other biological solutions to develop innovative, effective and clinically proven solutions that improve human health and create better lives in a growing world. To learn more, please visit www.novozymes.com.

Novozymes Synergia Life Sciences 2021
  • 2021
    Close Year
  • Healthcare
    Industry
  • Public
    Client Type
  • Strategic | Cross-border
    Transaction Type
  • India | Denmark
    Countries

Meet our Senior Team

Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.